Microbot Medical Reports Increased Q1 Losses and Cash Burn Amidst Initial Product Sales
MBOT sits 36% above its 52-week low of $1.6.
Summary
Microbot Medical reported higher Q1 losses and increased cash burn, even as it began generating initial revenues from its robotic system and started selling shares under a new ATM program.
Key Events · Earnings and Guidance · MBOT
-
Increased Net Loss
Net loss rose to $3.67 million in Q1 2026 from $2.60 million in Q1 2025.
-
Higher Operating Cash Burn
Cash used in operating activities increased to $5.05 million in Q1 2026 from $2.87 million in Q1 2025.
-
First Commercial Revenues
Generated $105,000 in revenue from the LIBERTY Endovascular Robotic System's limited market release.
-
ATM Offering Update
Initiated an At-The-Market offering of up to $39.2 million, with $17,000 in gross proceeds raised as of May 13, 2026.
Analysis · MBOT · Industrial Applications And Services
Microbot Medical's first-quarter report shows a significant increase in net loss and cash used in operating activities, despite generating initial revenues from its LIBERTY Endovascular Robotic System. The company is ramping up commercialization and continues to burn cash for R&D and sales activities. While management asserts a cash runway of over 12 months, the increased burn rate and the ongoing, albeit slow, utilization of a large At-The-Market offering highlight the need for continued capital.
At the time of this filing, MBOT was trading at $2.17 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $145.7M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.